Literature DB >> 17196977

Function blocking antibodies to neuropilin-1 generated from a designed human synthetic antibody phage library.

Wei-Ching Liang1, Mark S Dennis, Scott Stawicki, Yvan Chanthery, Qi Pan, Yongmei Chen, Charles Eigenbrot, JianPing Yin, Alexander W Koch, Xiumin Wu, Napoleone Ferrara, Anil Bagri, Marc Tessier-Lavigne, Ryan J Watts, Yan Wu.   

Abstract

Non-immune (naïve) antibody phage libraries have become an important source of human antibodies. The synthetic phage antibody library described here utilizes a single human framework with a template containing human consensus complementarity-determining regions (CDRs). Diversity of the libraries was introduced at select CDR positions using tailored degenerate and trinucleotide codons that mimic natural human antibodies. Neuropilin-1 (NRP1), a cell-surface receptor for both vascular endothelial growth factor (VEGF) and class 3 semaphorins, is expressed on endothelial cells and neurons. NRP1 is required for vascular development and is expressed widely in the developing vasculature. To investigate the possibility of function blocking antibodies to NRP1 as potential therapeutics, and study the consequence of targeting NRP1 in murine tumor models, panels of antibodies that cross-react with human and murine NRP1 were generated from a designed antibody phage library. Antibody (YW64.3) binds to the CUB domains (a1a2) of NRP1 and completely blocks Sema3A induced neuron collapse; antibody (YW107.4.87) binds to the coagulation factor V/VIII domains (b1b2) of NRP1 and blocks VEGF binding and VEGF induced cell migration. YW107.4.87 inhibits tumor growth in animal xenograft models. These antibodies have provided valuable tools to study the roles of NRP1 in vascular and tumor biology.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196977     DOI: 10.1016/j.jmb.2006.11.021

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  45 in total

1.  Maximizing tumour exposure to anti-neuropilin-1 antibody requires saturation of non-tumour tissue antigenic sinks in mice.

Authors:  Daniela Bumbaca; Hong Xiang; C Andrew Boswell; Ruediger E Port; Shannon L Stainton; Eduardo E Mundo; Sheila Ulufatu; Anil Bagri; Frank-Peter Theil; Paul J Fielder; Leslie A Khawli; Ben-Quan Shen
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

2.  An unexpected role of semaphorin3a-neuropilin-1 signaling in lymphatic vessel maturation and valve formation.

Authors:  Giorgia Jurisic; Hélène Maby-El Hajjami; Sinem Karaman; Alexandra M Ochsenbein; Annamari Alitalo; Shoib S Siddiqui; Carlos Ochoa Pereira; Tatiana V Petrova; Michael Detmar
Journal:  Circ Res       Date:  2012-06-20       Impact factor: 17.367

3.  Understanding differences between synthetic and natural antibodies can help improve antibody engineering.

Authors:  Anat Burkovitz; Yanay Ofran
Journal:  MAbs       Date:  2015-12-14       Impact factor: 5.857

4.  Structural basis for selective vascular endothelial growth factor-A (VEGF-A) binding to neuropilin-1.

Authors:  Matthew W Parker; Ping Xu; Xiaobo Li; Craig W Vander Kooi
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

5.  Structural and functional analysis of a C3b-specific antibody that selectively inhibits the alternative pathway of complement.

Authors:  Kenneth J Katschke; Scott Stawicki; Jianping Yin; Micah Steffek; Hongkang Xi; Lizette Sturgeon; Philip E Hass; Kelly M Loyet; Laura Deforge; Yan Wu; Menno van Lookeren Campagne; Christian Wiesmann
Journal:  J Biol Chem       Date:  2009-02-05       Impact factor: 5.157

6.  Population pharmacokinetic and pharmacodynamic modeling of MNRP1685A in cynomolgus monkeys using two-target quasi-steady-state (QSS) model.

Authors:  Yan Xin; Hong Xiang; Denise Jin; Frank-Peter Theil; Amita Joshi; Lisa A Damico-Beyer; Shuang Bai
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-03-01       Impact factor: 2.745

7.  A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid tumors.

Authors:  Colin D Weekes; Muralidhar Beeram; Anthony W Tolcher; Kyriakos P Papadopoulos; Lia Gore; Priti Hegde; Yan Xin; Ron Yu; L Mason Shih; Hong Xiang; Rainer K Brachmann; Amita Patnaik
Journal:  Invest New Drugs       Date:  2014-03-07       Impact factor: 3.850

8.  Structural studies of neuropilin/antibody complexes provide insights into semaphorin and VEGF binding.

Authors:  Brent A Appleton; Ping Wu; Janice Maloney; JianPing Yin; Wei-Ching Liang; Scott Stawicki; Kyle Mortara; Krista K Bowman; J Michael Elliott; William Desmarais; J Fernando Bazan; Anil Bagri; Marc Tessier-Lavigne; Alexander W Koch; Yan Wu; Ryan J Watts; Christian Wiesmann
Journal:  EMBO J       Date:  2007-11-08       Impact factor: 11.598

9.  Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling.

Authors:  Janet Jackman; Yongmei Chen; Arthur Huang; Barbara Moffat; Justin M Scheer; Steven R Leong; Wyne P Lee; Juan Zhang; Navneet Sharma; Yanmei Lu; Suhasini Iyer; Robert L Shields; Nancy Chiang; Michele C Bauer; Diana Wadley; Merone Roose-Girma; Richard Vandlen; Daniel G Yansura; Yan Wu; Lawren C Wu
Journal:  J Biol Chem       Date:  2010-05-05       Impact factor: 5.157

Review 10.  Semaphorins and their receptors in lung cancer.

Authors:  Vincent A Potiron; Joëlle Roche; Harry A Drabkin
Journal:  Cancer Lett       Date:  2008-07-14       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.